Clinical Trials
23 trialsNCT02779855 2026-03-10
Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT03802604 2025-09-09
PROMETEO
SOLTI Breast Cancer Research Group
Phase EARLY_PHASE1 Completed
NCT03554044 2025-05-21
T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer
University of California, San Francisco
Phase 1 Completed
NCT04330430 2025-03-12
NIVEC
The Netherlands Cancer Institute
Phase 2 Completed
NCT02819843 2025-01-29
A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT04068181 2025-01-07
Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).
Amgen
Phase 2 Completed
NCT03086642 2024-11-22
Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer
Columbia University
Phase 1 Completed
NCT03663712 2024-11-20
TEMPO
Duke University
Phase 1 Completed
NCT02509507 2024-08-06
MASTERKEY-318
Amgen
Phase 1/2 Completed
NCT02453191 2024-06-20
TVEC and Preop Radiation for Sarcoma (4 ml Dose)
University of Iowa
Phase 1/2 Completed
NCT01740297 2024-05-14
Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma
Amgen
Phase 1/2 Completed
NCT03256344 2024-05-14
Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases
Amgen
Phase 1 Completed
NCT02756845 2024-02-20
Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors
Amgen
Phase 1 Completed
NCT03458117 2022-03-18
20139157 T-VEC
University of Zurich
Phase 1 Completed
NCT02366195 2021-11-30
TVEC-325
Amgen
Phase 2 Completed
NCT02626000 2021-09-08
MASTERKEY232
Amgen
Phase 1 Completed
NCT03555032 2021-08-18
TITAN
Royal Marsden NHS Foundation Trust
Phase 1/2 Completed
NCT02014441 2019-11-20
Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec
Amgen
Phase 2 Completed
NCT00769704 2016-07-13
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
BioVex Limited
Phase 3 Completed
NCT00402025 2016-04-15
Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer
BioVex Limited
Phase 1 Completed
NCT00289016 2015-12-18
A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma
BioVex Limited
Phase 2 Completed
NCT01368276 2015-12-18
An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma
BioVex Limited
Phase 3 Completed
NCT02574260 2015-12-17
An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016)
BioVex Limited
Phase 2 Completed